WallStSmart
MGRX

Mangoceuticals, Inc. Common Stock

NASDAQ: MGRX · HEALTHCARE · HEALTH INFORMATION SERVICES

$0.39
-2.09% today

Updated 2026-06-03

Market cap
$6.35M
P/E ratio
P/S ratio
14.78x
EPS (TTM)
$-1.27
Dividend yield
52W range
$0 – $3
Volume
1.1M

Mangoceuticals, Inc. Common Stock (MGRX) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20212022202320242025
Total assets$22550.00$1.00M$1.05M$15.37M$16.09M
Cash & equivalents$22550.00$682860.00$739006.00$58653.00$1.49M
Current assets$22550.00$694605.00$818460.00$75595.00$1.55M
Total liabilities$39270.00$389257.00$276039.00$1.43M$890568.00
Current liabilities$39270.00$260577.00$211078.00$1.43M$890568.00
Long-term debt
Shareholder equity$-16720.00$614030.00$774754.00$13.95M$15.20M
Retained earnings$-17701.00$-2.02M$-11.23M$-20.81M$-40.65M
Accounts receivable$0.00
Inventory$0.00$18501.00$0.00
Goodwill

Frequently asked questions

What is Mangoceuticals, Inc. Common Stock's revenue?

Mangoceuticals, Inc. Common Stock's trailing twelve-month revenue is $414580.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MGRX?

In its most recent fiscal year, MGRX ran a gross margin of 54.91%, an operating margin of -4,200.46%, and a net margin of -4,526.86%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MGRX generate?

MGRX produced $-5.85M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MGRX's balance sheet healthy?

MGRX holds $1.49M in cash and equivalents against — in long-term debt, on $15.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.